Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Follow-Up, Open-Label, Research Evaluation of Sustained Treatment With Aficamten (CK-3773274) in Hypertrophic Cardiomyopathy (HCM)

NCT04848506 is registered in ClinicalTrials.gov with Cytokinetics as lead sponsor.

NCT NCT04848506
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04848506 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Follow-Up, Open-Label, Research Evaluation of Sustained Treatment With Aficamten (CK-3773274) in Hypertrophic Cardiomyopathy (HCM)
Lead sponsor
Cytokinetics
Phase
Phase 2/3
Overall status
Enrolling by invitation
Start date
May 6, 2021
Completion date
March 31, 2029
Enrollment
900 (estimated)
Sites
141

Conditions

As the registry lists them; a condition with its own page is linked.

symptomatic hypertrophic cardiomyopathy (hcm)